158 related articles for article (PubMed ID: 34404029)
1. Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed.
Geer MJ; Foucar CE; Devata S; Benitez L; Perissinotti AJ; Marini BL; Bixby D
J Natl Compr Canc Netw; 2021 Aug; 19(11):1272-1275. PubMed ID: 34404029
[TBL] [Abstract][Full Text] [Related]
2. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid.
Horna P; Zhang L; Sotomayor EM; Lancet JE; Moscinski LC
Am J Clin Pathol; 2014 Oct; 142(4):546-52. PubMed ID: 25239423
[TBL] [Abstract][Full Text] [Related]
4. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
Agadir A; Cornic M; Lefebvre P; Gourmel B; Jérôme M; Degos L; Fenaux P; Chomienne C
J Clin Oncol; 1995 Oct; 13(10):2517-23. PubMed ID: 7595702
[TBL] [Abstract][Full Text] [Related]
6. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group.
Fenaux P; Chastang C; Degos L
Leukemia; 1994; 8 Suppl 2():S42-7. PubMed ID: 7815836
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
8. All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies.
Tallman MS
Semin Hematol; 1994 Oct; 31(4 Suppl 5):38-48. PubMed ID: 7831584
[TBL] [Abstract][Full Text] [Related]
9. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
11. The present status in all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia patients: further understanding and comprehensive strategy are required in the future.
Chen ZX; Tao RF; Xia XM
Leuk Lymphoma; 1992 Nov; 8(4-5):247-52. PubMed ID: 1290955
[TBL] [Abstract][Full Text] [Related]
12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
13. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
14. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells.
Visani G; Tosi P; Ottaviani E; Zaccaria A; Baccini C; Manfroi S; Pastano R; Remiddi C; Morelli A; Molinari AL; Zanchini R; Tura S
Eur J Haematol; 1996 Oct; 57(4):301-6. PubMed ID: 8982293
[TBL] [Abstract][Full Text] [Related]
16. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
17. All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia.
Bapna A; Nair R; Tapan KS; Nair CN; Kadam P; Gladstone B; Advani SH
Pediatr Hematol Oncol; 1998; 15(3):243-8. PubMed ID: 9615322
[TBL] [Abstract][Full Text] [Related]
18. Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.
Dubois C; Schlageter MH; de Gentile A; Balitrand N; Toubert ME; Krawice I; Fenaux P; Castaigne S; Najean Y; Degos L
Leukemia; 1994 Oct; 8(10):1750-7. PubMed ID: 7523800
[TBL] [Abstract][Full Text] [Related]
19. Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid.
Giralt S; O'Brien S; Weeks E; Luna M; Kantarjian H
Leuk Lymphoma; 1994 Aug; 14(5-6):453-6. PubMed ID: 7812204
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
